Arno AR-42 for neurofibromatosis type 2 receives EMA orphan-drug designation Arno Therapeutics.

announced today that its investigational compound referred to as AR-42 has been granted orphan-medication designation by the European Medications Agency’s Committee for Orphan Medicinal Items for the treatment of neurofibromatosis type 2 . NF2 is normally a rare genetic disorder seen as a the growth of noncancerous tumors in the mind and spinal cord, juvenile cataracts and neurofibromas of the skin. The disease is caused by mutations in a gene which is important in stopping cells from dividing uncontrollably.Imaging experts and allied experts continue to work to reduce the amount of false-positive examinations that patients experience and make sure that follow-up exams are as minimally invasive as possible. Physicians also continue steadily to refine the reporting procedure to ensure that patients receive outcomes as quickly as possible. Related StoriesStudy shows rare HER2 missense mutations usually do not spread breast cancer on their ownNew results reveal association between colorectal cancer tumor and melanoma drug treatmentMeat-rich diet may increase kidney malignancy riskPrimary National Lung Screening Trial outcomes showed that screening high-risk sufferers for lung cancers using low-dose computed tomography scans significantly reduced lung cancer deaths.